"Uric Acid" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An oxidation product, via XANTHINE OXIDASE, of oxypurines such as XANTHINE and HYPOXANTHINE. It is the final oxidation product of purine catabolism in humans and primates, whereas in most other mammals URATE OXIDASE further oxidizes it to ALLANTOIN.
Descriptor ID |
D014527
|
MeSH Number(s) |
D03.132.960.877 D03.633.100.759.758.824.877
|
Concept/Terms |
Uric Acid- Uric Acid
- Acid, Uric
- 2,6,8-Trihydroxypurine
- Trioxopurine
Sodium Urate Monohydrate- Sodium Urate Monohydrate
- Monohydrate, Sodium Urate
- Urate Monohydrate, Sodium
- Monosodium Urate Monohydrate
- Monohydrate, Monosodium Urate
- Urate Monohydrate, Monosodium
- Sodium Acid Urate Monohydrate
- Sodium Urate
- Urate, Sodium
- Monosodium Urate
- Urate, Monosodium
- Sodium Acid Urate
- Acid Urate, Sodium
- Urate, Sodium Acid
|
Below are MeSH descriptors whose meaning is more general than "Uric Acid".
Below are MeSH descriptors whose meaning is more specific than "Uric Acid".
This graph shows the total number of publications written about "Uric Acid" by people in this website by year, and whether "Uric Acid" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2000 | 2 | 0 | 2 |
2009 | 1 | 0 | 1 |
2014 | 1 | 1 | 2 |
2015 | 0 | 1 | 1 |
2016 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Uric Acid" by people in Profiles.
-
Rationale and design of the randomized evaluation of an Ambulatory Care Pharmacist-Led Intervention to Optimize Urate Lowering Pathways (RAmP-UP) Study. Contemp Clin Trials. 2016 09; 50:106-15.
-
A Pharmacist-Staffed, Virtual Gout Management Clinic for Achieving Target Serum Uric Acid Levels: A Randomized Clinical Trial. Perm J. 2016; 20(3):15-234.
-
Patient and clinical characteristics associated with gout flares in an integrated healthcare system. Rheumatol Int. 2015 Nov; 35(11):1799-807.
-
Genome-wide association study identifies ABCG2 (BCRP) as an allopurinol transporter and a determinant of drug response. Clin Pharmacol Ther. 2015 May; 97(5):518-25.
-
Modifiable factors associated with allopurinol adherence and outcomes among patients with gout in an integrated healthcare system. J Rheumatol. 2015 Mar; 42(3):504-12.
-
Relation of serum uric acid levels and outcomes among patients hospitalized for worsening heart failure with reduced ejection fraction (from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan trial). Am J Cardiol. 2014 Dec 01; 114(11):1713-21.
-
Effect of urate-lowering therapies on renal disease progression in patients with hyperuricemia. J Rheumatol. 2014 May; 41(5):955-62.
-
Effectiveness of a pharmacist-based gout care management programme in a large integrated health plan: results from a pilot study. BMJ Open. 2014 Jan 10; 4(1):e003627.
-
Plasma renin activity (PRA) levels and antihypertensive drug use in a large healthcare system. Am J Hypertens. 2012 Mar; 25(3):379-88.
-
The dynamics of chronic gout treatment: medication gaps and return to therapy. Am J Med. 2010 Jan; 123(1):54-9.